New Long-Acting malaria shot tested in humans for first time
NCT ID NCT06558643
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects and injection site reactions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MMV371 long-acting injection
What this could lead to
If successful, this could lead to a long-acting injectable malaria preventive or treatment, reducing the need for daily pills.
What could go wrong
This is a very early Phase 1 safety study in only 32 healthy people. It does not test if the drug actually prevents or treats malaria, and side effects or injection site reactions may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quotient Sciences
Ruddington, Nottingham, NG11 6JS, United Kingdom